Q3 2023 Results - Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
Novartis delivers strong sales growth, robust margin expansion
and raises guidance. Successfully spun Sandoz
SUMMARY
Growth and productivity1
% CC
Core margin
37.4% (+270 bps)
Core margin
36.9% (+290 bps)
Successful spin-off of Sandoz
Completed October 4, 2023
Several major innovation milestones in Q3
CosentyxⓇ IV formulation approved in US (PSA, AS, nr-axSpA)
LeqvioⓇ approved in China and Japan
KisqaliⓇ submitted in EU; US submission planned in Q4 2023
Clinically meaningful and statistically significant
■
21%
19%
■
12%
10%
Sales
Core Opinc
Sales
Q3
Core Oplnc
9M
FY 2023 guidance raised¹
Sales expected to grow high single digit; Core Oplnc expected
to grow mid to high teens (from low double digit to mid teens)
Ph3 data for multiple assets with blockbuster potential
■ PluvictoⓇ mCRPC pre-taxane
■ Iptacopan IgAN
■ Remibrutinib CSU
■ LutatheraⓇ GEP-NETS
1. Continuing operations. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
Oplnc operating income.
4 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation